Targeting the BAG2/CHIP axis promotes gastric cancer apoptosis by blocking apoptosome assembly

Area of Science:

• Oncology
• Molecular Biology
• Cell Death Research

Background:

• Apoptosis is crucial in gastric cancer (GC) treatment.
• BCL2-associated athanogene 2 (BAG2) inhibits apoptosis by interacting with regulators.
• BAG2 is implicated in cancer progression and patient outcomes.

Purpose of the Study:

• To investigate BAG2's role as a prognostic factor in gastric cancer.
• To elucidate the molecular mechanisms by which BAG2 affects GC cell behavior.
• To evaluate the therapeutic potential of targeting the BAG2 complex in GC.

Main Methods:

• Analysis of BAG2 expression and patient outcomes.
• In vitro studies using BAG2-overexpressing and deficient GC cells.
• Investigation of protein-protein interactions (BAG2, CHIP, HSP70, Apaf1).
• Assessment of apoptosis markers (cytochrome C release, apoptotic body formation).
• Screening and evaluation of FIIN-2 as a BAG2 complex inhibitor.

Main Results:

• BAG2 expression correlates with unfavorable prognosis in GC patients.
• BAG2 upregulation enhances GC cell proliferation, migration, and invasion while inhibiting apoptosis.
• BAG2 inhibits Heat shock protein 70 (HSP70) ubiquitination and degradation via CHIP, increasing HSP70-Apaf1 binding.
• This mechanism reduces mitochondrial cytochrome C release and inhibits apoptotic body formation.
• FIIN-2 blocks BAG2-CHIP binding, inhibiting BAG2-mediated malignant progression.

Conclusions:

• BAG2 is an independent prognostic factor in gastric cancer, promoting malignancy by inhibiting apoptosis.
• The mechanism involves BAG2-CHIP interaction, stabilizing HSP70 and suppressing apoptosis.
• FIIN-2 demonstrates therapeutic potential by targeting the BAG2 complex for gastric cancer treatment.